The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 8: 1097 - 1104

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.08.002

Feature Reports：neuropathy

Effect of EGCG on MPTP⁃induced Parkinson′s model mice via autophagy⁃lysosomal pathway

  • Xu ZHOU ,
  • Ranran LU ,
  • Fangli REN ,
  • Xiaoyu PENG ,
  • Xinling. YANG
Expand
  • Department of Neurology，the Second Affiliated Hospital of Xinjiang Medical University，Urumqi 830028，Xinjiang，China

Received date: 2024-12-26

  Online published: 2025-04-30

Fold

Abstract

Objective To investigate the protective effect of epigallocatechin gallate （EGCG） on 1?methyl?4?phenyl?1，2，3，6?tetrahydropyridine （MPTP）?induced Parkinson's disease model mice. Methods Twenty?eight male C57BL/6J mice aged 6 ~ 8 weeks were randomly divided into four groups： the control group， the model group， the low?dose EGCG group［25 mg/（kg·d）］， and the high?dose EGCG group［50 mg/（kg·d）］. A Parkinson's disease （PD） mouse model was established by intraperitoneal injection of MPTP at a dose of 30 mg/ （kg·d） for 7 consecutive days. The protective effect of EGCG on MPTP?induced Parkinson's model mice was analyzed through behavioral index detection and Western blot method. Results （1）In the behavioral tests， compared with the model group， the movement distance and speed of mice treated with low?and high?dose EGCG were significantly improved （both P values < 0.001）. The mice in the high?dose EGCG treatment group also showed a significant advantage in the percentage of the central path distance （P < 0.001）. （2）Compared with the control group， the deposition of α?synuclein in the model group increased significantly （P < 0.001）. Compared with the model group， both the low?and high?dose EGCG groups reduced the deposition of α?synuclein （both P < 0.001）. （3）Compared with the control group， the expression levels of Beclin 1 and LC3 proteins in the substantia nigra region of mice in the model group decreased significantly （both P < 0.001）， while the expression level of p62 protein increased significantly （P < 0.001）. After treatment with EGCG， compared with the model group， the expression levels of Beclin 1 and LC3 proteins in mice of the low?dose EGCG group increased to varying degrees （P < 0.01； P < 0.001）， and the expression level of p62 protein decreased significantly （P < 0.001）. In the high?dose EGCG group， the expression levels of Beclin 1 and LC3 proteins increased significantly （both P < 0.001）， and the expression level of p62 protein decreased significantly （P < 0.001）. Conclusion EGCG reduces alpha?synuclein deposition via the autophagy?lysosomal pathway and protects against MPTP-induced Parkinson's disease model mice.

Key words： Parkinson's disease; alpha?synuclein; epigallocatechin gallate; autophagy; autophagy?lysosome way; 1?methyl?4?phenyl?1，2，3，6?tetrahydropyridine

Cite this article

Xu ZHOU , Ranran LU , Fangli REN , Xiaoyu PENG , Xinling. YANG . Effect of EGCG on MPTP⁃induced Parkinson′s model mice via autophagy⁃lysosomal pathway[J]. The Journal of Practical Medicine, 2025 , 41(8) : 1097 -1104 . DOI: 10.3969/j.issn.1006-5725.2025.08.002

References

1 PANKRATZ N， FOROUD T. Genetics of Parkinson disease［J］. Genet Med， 2007， 9（12）：801-811. doi:10.1097/gim.0b013e31815bf97c
2 DE LAU L M， BRETELER M M. Epidemiology of Parkinson's disease［J］. Lancet Neurol， 2006， 5（6）：525-535. doi:10.1016/s1474-4422(06)70471-9
3 XILOURI M， BREKK O R， STEFANIS L. Autophagy and Alpha-Synuclein： Relevance to Parkinson's Disease and Related Synucleopathies［J］. Mov Disord， 2016，31（2）：178-192.
4 GON?ALVES P B， SODERO A C R， CORDEIRO Y. Green Tea Epigallocatechin-3-gallate （EGCG） Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases［J］. Biomolecules， 2021，11（5）：767. doi:10.3390/biom11050767
5 GAO W， WANG Y， WANG F， et al. Ergothioneine exerts neuroprotective effects in Parkinson's disease： Targeting α-synuclein aggregation and oxidative stress［J］. Food Res Int， 2025，201：115590. doi:10.1016/j.foodres.2024.115590
6 GADHE L， SAKUNTHALA A， MUKHERJEE S， et al. Intermediates of α-synuclein aggregation： Implications in Parkinson's disease pathogenesis［J］. Biophys Chem， 2022，281：106736. doi:10.1016/j.bpc.2021.106736
7 DE WET S， THEART R， LOOS B. Cogs in the autophagic machine-equipped to combat dementia-prone neurodegenerative diseases［J］. Front Mol Neurosci， 2023，16：1225227. doi:10.3389/fnmol.2023.1225227
8 LIANG Y， ZHONG G， REN M， et al. The Role of Ubiquitin-Proteasome System and Mitophagy in the Pathogenesis of Parkinson's Disease［J］. Neuromolecular Med， 2023，25（4）：471-488. doi:10.1007/s12017-023-08755-0
9 FISHMAN-JACOB T， YOUDIM M B H. A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component， SKP1A［J］. J Neural Transm （Vienna）， 2024，131（6）：675-707. doi:10.1007/s00702-023-02687-6
10 DROBNY A， BOROS F A， BALTA D， et al. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models［J］. Transl Neurodegener， 2023，12（1）：31. doi:10.1186/s40035-023-00363-z
11 SENKEVICH K， GAN-OR Z. Autophagy lysosomal pathway dysfunction in Parkinson's disease； evidence from human genetics［J］. Parkinsonism Relat Disord， 2020，73：60-71. doi:10.1016/j.parkreldis.2019.11.015
12 MALAR D S， PRASANTH M I， BRIMSON J M， et al. Neuroprotective Properties of Green Tea （Camellia sinensis） in Parkinson's Disease： A Review［J］. Molecules， 2020，25（17）：3926. doi:10.3390/molecules25173926
13 PICCOLI G， VOLTA M. LRRK2 along the Golgi and lysosome connection： A jamming situation［J］. Biochem Soc Trans， 2021，49（5）：2063-2072. doi:10.1042/bst20201146
14 LU R， ZHOU X， ZHANG L， et al. Nrf2 Deficiency Exacerbates Parkinson's Disease by Aggravating NLRP3 Inflammasome Activation in MPTP-Induced Mouse Models and LPS-Induced BV2 Cells［J］. J Inflamm Res， 2024，17：6277-6295. doi:10.2147/jir.s478683
15 RUDENOK M M， SHADRINA M I， FILATOVA E V， et al. Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson's Disease［J］. Life （Basel）， 2022，12（5）：751. doi:10.3390/life12050751
16 胡梦妮，张小蕾，荣臻，等. 电针对MPTP诱导帕金森病小鼠FoXO1/NLRP3通路介导神经炎症的影响［J］. 实用医学杂志， 2024， 40（11）： 1494-1499. doi:10.3969/j.issn.1006-5725.2024.11.005
17 LI S， WANG Z， LIU G， et al. Neurodegenerative diseases and catechins： （-）-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress［J］. Front Nutr，2024，11：1425839. doi:10.3389/fnut.2024.1425839
18 逯冉冉，周旭，张利杰，等. 富马酸二甲酯减轻帕金森病模型鼠神经损伤的作用机制［J］. 中国组织工程研究， 2025，29（5）：989-994. doi:10.12307/2025.294
19 PRASAD E M， HUNG S Y. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease［J］. Antioxidants （Basel）， 2020，9（10）：1007. doi:10.3390/antiox9101007
20 姜宗飞，杨文平，司锋，等. 中国帕金森病发病负担分析及预测［J］. 中华神经医学杂志， 2024，23（12）：1205-1210.
21 PAYNE A， NAHASHON S， TAKA E， et al. Epigallocatechin-3-Gallate （EGCG）： New Therapeutic Perspectives for Neuroprotection， Aging， and Neuroinflammation for the Modern Age［J］. Biomolecules， 2022，12（3）：371. doi:10.3390/biom12030371
22 KIM H S， QUON M J， KIM J A. New insights into the mechanisms of polyphenols beyond antioxidant properties； lessons from the green tea polyphenol， epigallocatechin 3-gallate［J］. Redox Biol， 2014，2：187-195. doi:10.1016/j.redox.2013.12.022
23 LIU Y， LONG Y， FANG J， et al. Advances in the Anti-Atherosclerotic Mechanisms of Epigallocatechin Gallate［J］. Nutrients， 2024，16（13）：2074. doi:10.3390/nu16132074
24 SHARMA V， CHAUDHARY A A， BAWARI S， et al. Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management［J］. Front Pharmacol， 2024，15：1414790. doi:10.3389/fphar.2024.1414790
25 TALIB WH， AWAJAN D， ALQUDAH A， et al. Targeting Cancer Hallmarks with Epigallocatechin Gallate （EGCG）： Mechanistic Basis and Therapeutic Targets［J］. Molecules， 2024，29（6）：1373. doi:10.3390/molecules29061373
26 CHEN Y， LIU Z， GONG Y. Neuron-immunity communication： Mechanism of neuroprotective effects in EGCG［J］. Crit Rev Food Sci Nutr， 2024，64（25）：9333-9352. doi:10.1080/10408398.2023.2212069
27 ESMAEELPANAH E， RAZAVI B M， VAHDATI HASANI F， et al. Evaluation of epigallocatechin gallate and epicatechin gallate effects on acrylamide-induced neurotoxicity in rats and cytotoxicity in PC 12 cells［J］. Drug Chem Toxicol， 2018，41（4）：441-448. doi:10.1080/01480545.2017.1381108
28 XIE X， WAN J， ZHENG X， et al. Synergistic effects of epigallocatechin gallate and l-theanine in nerve repair and regeneration by anti-amyloid damage， promoting metabolism， and nourishing nerve cells［J］. Front Nutr， 2022，9：951415. doi:10.3389/fnut.2022.951415
29 NAKAMURA S， YOSHIMORI T. Autophagy and Longevity［J］. Mol Cells， 2018，41（1）：65-72.
30 LU R， ZHANG L， YANG X. Interaction between autophagy and the NLRP3 inflammasome in Alzheimer's and Parkinson's disease［J］. Front Aging Neurosci， 2022，14：1018848. doi:10.3389/fnagi.2022.1018848
31 LI R， LU Y， ZHANG Q， et al. Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model［J］. Autophagy， 2022，18（3）：559-575. doi:10.1080/15548627.2021.1937897
32 XUAN F， JIAN J. Epigallocatechin gallate exerts protective effects against myocardial ischemia/reperfusion injury through the PI3K/Akt pathway-mediated inhibition of apoptosis and the restoration of the autophagic flux［J］. Int J Mol Med， 2016，38（1）：328-336. doi:10.3892/ijmm.2016.2615
33 ZHAO L， LIU S， XU J， et al. A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells［J］. Cell Death Dis， 2017，8（11）：e3160. doi:10.1038/cddis.2017.563
34 ZHANG S， CAO M， FANG F. The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress （ERS）- Induced Apoptosis of Human Diseases［J］. Med Sci Monit， 2020，26：e924558. doi:10.12659/msm.924558
35 KHAN M R， YIN X， KANG S U， et al. Enhanced mTORC1 signaling and protein synthesis in pathologic α-synuclein cellular and animal models of Parkinson's disease［J］. Sci Transl Med，2023，15（724）：eadd0499. doi:10.1126/scitranslmed.add0499
36 BAYATI A， AYOUBI R， AGUILA A， et al. Modeling Parkinson's disease pathology in human dopaminergic neurons by sequential exposure to α-synuclein fibrils and proinflammatory cytokines［J］. Nat Neurosci， 2024，27（12）：2401-2416. doi:10.1038/s41593-024-01775-4
37 ARMELI F， MENGONI B， LASKIN D L， et al. Interplay among Oxidative Stress， Autophagy， and the Endocannabinoid System in Neurodegenerative Diseases： Role of the Nrf2- p62/SQSTM1 Pathway and Nutraceutical Activation［J］. Curr Issues Mol Biol，2024，46（7）：6868-6884. doi:10.3390/cimb46070410
38 丁新玲，孙会艳，李强，等. EGCG对帕金森病神经保护作用机制研究进展［J］. 中国药理学通报， 2023，39（10）：1806-1810.
39 ZHANG Y， WU H， XU C， et al. （-）-Epigallocatechin gallate alleviates chronic unpredictable mild stress-induced depressive symptoms in mice by regulating the mTOR autophagy pathway and inhibiting NLRP3 inflammasome activation［J］. Food Sci Nutr， 2023，12（1）：459-470. doi:10.1002/fsn3.3761
Options
Outlines

/

〈 〉